Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Archives of Virology
Published in: Archives of Virology 8/2011

01-08-2011 | Original Article

Caspase- and p38-MAPK-dependent induction of apoptosis in A549 lung cancer cells by Newcastle disease virus

Authors: Jianchun Bian, Kai Wang, Xiangang Kong, Huairan Liu, Fei Chen, Maozhi Hu, Xiaorong Zhang, Xinan Jiao, Baoxue Ge, Yantao Wu, Songshu Meng

Published in: Archives of Virology | Issue 8/2011

Login to get access

Abstract

Newcastle disease virus (NDV) has a potential oncolytic effect due to its ability to induce apoptosis in tumor cells. However, previous studies have indicated discrepancies regarding the apoptosis signaling pathways induced by NDV in tumor cells. Here, we show that NDV infection induces simultaneous activation of intrinsic and extrinsic death pathways in A549 human lung cancer cells. In contrast, endoplasmic reticulum (ER) stress is not activated in NDV-induced apoptosis. We demonstrate for the first time that mitogen-activated protein kinase (MAPK) pathways are activated in NDV-infected A549 cells, and p38 MAPK is involved in NDV-induced cell death. Together, our findings provide novel insights into the underlying mechanisms by which NDV induces apoptosis in tumor cells.
Literature
1.
Batliwalla FM, Bateman BA, Serrano D, Murray D, Macphail S, Maino VC, Ansel JC, Gregersen PK, Armstrong CA (1998) A 15-year follow-up of AJCC stage III malignant melanoma patients treated postsurgically with Newcastle disease virus (NDV) oncolysate and determination of alterations in the CD8 T cell repertoire. Mol Med 4:783–794PubMed
2.
Brugh M, Beard CW (1984) Atypical disease produced in chickens by Newcastle disease virus isolated from exotic birds. Avian Dis 28:482–488PubMedCrossRef
3.
Cassel WA, Garrett RE (1965) Newcastle disease virus as an antineoplastic agent. Cancer 18:863–868PubMedCrossRef
4.
Csatary LK, Moss RW, Beuth J, Torocsik B, Szeberenyi J, Bakacs T (1999) Beneficial treatment of patients with advanced cancer using a Newcastle disease virus vaccine (MTH-68/H). Anticancer Res 19:635–638PubMed
5.
Dortmans JC, Rottier PJ, Koch G, Peeters BP (2010) The viral replication complex is associated with the virulence of Newcastle disease virus. J Virol 84:10113–10120PubMedCrossRef
6.
Ekert PG, Vaux DL (1997) Apoptosis and the immune system. Br Med Bull 53:591–603PubMed
7.
Elankumaran S, Rockemann D, Samal SK (2006) Newcastle disease virus exerts oncolysis by both intrinsic and extrinsic caspase-dependent pathways of cell death. J Virol 80:7522–7534PubMedCrossRef
8.
Elankumaran S, Chavan V, Qiao D, Shobana R, Moorkanat G, Biswas M, Samal SK (2010) Type I interferon-sensitive recombinant Newcastle disease virus for oncolytic virotherapy. J Virol 84:3835–3844PubMedCrossRef
9.
Fabian Z, Csatary CM, Szeberenyi J, Csatary LK (2007) p53-independent endoplasmic reticulum stress-mediated cytotoxicity of a Newcastle disease virus strain in tumor cell lines. J Virol 81:2817–2830PubMedCrossRef
10.
Fiola C, Peeters B, Fournier P, Arnold A, Bucur M, Schirrmacher V (2006) Tumor selective replication of Newcastle disease virus: association with defects of tumor cells in antiviral defence. Int J Cancer 119:328–338PubMedCrossRef
11.
Freeman AI, Zakay-Rones Z, Gomori JM, Linetsky E, Rasooly L, Greenbaum E, Rozenman-Yair S, Panet A, Libson E, Irving CS, Galun E, Siegal T (2006) Phase I/II trial of intravenous NDV-HUJ oncolytic virus in recurrent glioblastoma multiforme. Mol Ther 13:221–228PubMedCrossRef
12.
13.
Krishnamurthy S, Takimoto T, Scroggs RA, Portner A (2006) Differentially regulated interferon response determines the outcome of Newcastle disease virus infection in normal and tumor cell lines. J Virol 80:5145–5155PubMedCrossRef
14.
Lazar I, Yaacov B, Shiloach T, Eliahoo E, Kadouri L, Lotem M, Perlman R, Zakay-Rones Z, Panet A, Ben-Yehuda D (2010) The oncolytic activity of Newcastle disease virus NDV-HUJ on chemoresistant primary melanoma cells is dependent on the proapoptotic activity of the inhibitor of apoptosis protein Livin. J Virol 84:639–646PubMedCrossRef
15.
Luo H, Yanagawa B, Zhang J, Luo Z, Zhang M, Esfandiarei M, Carthy C, Wilson JE, Yang D, McManus BM (2002) Coxsackievirus B3 replication is reduced by inhibition of the extracellular signal-regulated kinase (ERK) signaling pathway. J Virol 76:3365–3373PubMedCrossRef
16.
Meng S, Bai H, Hu M, Liu W, Wang L, Wu Y, Jiao X, Fan J (2009) Mechanisms of in vitro anti-tumor effects of a Newcastle disease virus. Wei Sheng Wu Xue Bao 49:512–517PubMed
17.
Meng S, Gui Q, Xu Q, Lu K, Jiao X, Fan J, Ge B, Ke Y, Zhang S, Wu J, Wang C (2010) Association of Shp2 with phosphorylated IL-22R1 is required for interleukin-22-induced MAP kinase activation. J Mol Cell Biol 2:223–230PubMedCrossRef
18.
Momoi T (2004) Caspases involved in ER stress-mediated cell death. J Chem Neuroanat 28:101–105PubMed
19.
Nagai Y (1999) Paramyxovirus replication and pathogenesis. Reverse genetics transforms understanding. Rev Med Virol 9:83–99PubMedCrossRef
20.
Nakagawa T, Zhu H, Morishima N, Li E, Xu J, Yankner BA, Yuan J (2000) Caspase-12 mediates endoplasmic-reticulum-specific apoptosis and cytotoxicity by amyloid-beta. Nature 403:98–103PubMedCrossRef
21.
Pecora AL, Rizvi N, Cohen GI, Meropol NJ, Sterman D, Marshall JL, Goldberg S, Gross P, O’Neil JD, Groene WS, Roberts MS, Rabin H, Bamat MK, Lorence RM (2002) Phase I trial of intravenous administration of PV701, an oncolytic virus, in patients with advanced solid cancers. J Clin Oncol 20:2251–2266PubMedCrossRef
22.
Pfirschke C, Schirrmacher V (2009) Cross-infection of tumor cells by contact with T lymphocytes loaded with Newcastle disease virus. Int J Oncol 34:951–962PubMed
23.
Puhlmann J, Puehler F, Mumberg D, Boukamp P, Beier R (2010) Rac1 is required for oncolytic NDV replication in human cancer cells and establishes a link between tumorigenesis and sensitivity to oncolytic virus. Oncogene 29:2205–2216PubMedCrossRef
24.
Rathmell JC, Thompson CB (1999) The central effectors of cell death in the immune system. Annu Rev Immunol 17:781–828PubMedCrossRef
25.
Ravindra PV, Tiwari AK, Ratta B, Chaturvedi U, Palia SK, Chauhan RS (2009) Newcastle disease virus-induced cytopathic effect in infected cells is caused by apoptosis. Virus Res 141:13–20PubMedCrossRef
26.
Reddy KB, Nabha SM, Atanaskova N (2003) Role of MAP kinase in tumor progression and invasion. Cancer Metastasis Rev 22:395–403PubMedCrossRef
27.
Reichard KW, Lorence RM, Cascino CJ, Peeples ME, Walter RJ, Fernando MB, Reyes HM, Greager JA (1992) Newcastle disease virus selectively kills human tumor cells. J Surg Res 52:448–453PubMedCrossRef
28.
Schirrmacher V, Haas C, Bonifer R, Ahlert T, Gerhards R, Ertel C (1999) Human tumor cell modification by virus infection: an efficient and safe way to produce cancer vaccine with pleiotropic immune stimulatory properties when using Newcastle disease virus. Gene Ther 6:63–73PubMedCrossRef
29.
Schroder M, Kaufman RJ (2005) ER stress and the unfolded protein response. Mutat Res 569:29–63PubMed
30.
Si X, Luo H, Morgan A, Zhang J, Wong J, Yuan J, Esfandiarei M, Gao G, Cheung C, McManus BM (2005) Stress-activated protein kinases are involved in coxsackievirus B3 viral progeny release. J Virol 79:13875–13881PubMedCrossRef
31.
Sinkovics JG, Horvath JC (2000) Newcastle disease virus (NDV): brief history of its oncolytic strains. J Clin Virol 16:1–15PubMedCrossRef
32.
33.
Sumbayev VV, Yasinska IM (2006) Role of MAP kinase-dependent apoptotic pathway in innate immune responses and viral infection. Scand J Immunol 63:391–400PubMedCrossRef
34.
Szeberenyi J, Fabian Z, Torocsik B, Kiss K, Csatary LK (2003) Newcastle disease virus-induced apoptosis in PC12 pheochromocytoma cells. Am J Ther 10:282–288PubMedCrossRef
35.
Weaver BK, Ando O, Kumar KP, Reich NC (2001) Apoptosis is promoted by the dsRNA-activated factor (DRAF1) during viral infection independent of the action of interferon or p53. FASEB J 15:501–515PubMedCrossRef
36.
Wheelock EF, Dingle JH (1964) Observations on the repeated administration of viruses to a patient with acute leukemia. A preliminary report. N Engl J Med 271:645–651PubMedCrossRef
37.
Wise MG, Suarez DL, Seal BS, Pedersen JC, Senne DA, King DJ, Kapczynski DR, Spackman E (2004) Development of a real-time reverse-transcription PCR for detection of Newcastle disease virus RNA in clinical samples. J Clin Microbiol 42:329–338PubMedCrossRef
38.
Xia Z, Dickens M, Raingeaud J, Davis RJ, Greenberg ME (1995) Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis. Science 270:1326–1331PubMedCrossRef
39.
Yaacov B, Eliahoo E, Lazar I, Ben-Shlomo M, Greenbaum I, Panet A, Zakay-Rones Z (2008) Selective oncolytic effect of an attenuated Newcastle disease virus (NDV-HUJ) in lung tumors. Cancer Gene Ther 15:795–807PubMedCrossRef
40.
Yang TC, Shiu SL, Chuang PH, Lin YJ, Wan L, Lan YC, Lin CW (2009) Japanese encephalitis virus NS2B-NS3 protease induces caspase 3 activation and mitochondria-mediated apoptosis in human medulloblastoma cells. Virus Res 143:77–85PubMedCrossRef
Metadata
Title
Caspase- and p38-MAPK-dependent induction of apoptosis in A549 lung cancer cells by Newcastle disease virus
Authors
Jianchun Bian
Kai Wang
Xiangang Kong
Huairan Liu
Fei Chen
Maozhi Hu
Xiaorong Zhang
Xinan Jiao
Baoxue Ge
Yantao Wu
Songshu Meng
Publication date
01-08-2011
Publisher
Springer Vienna
Published in
Archives of Virology / Issue 8/2011
Print ISSN: 0304-8608
Electronic ISSN: 1432-8798
DOI
https://doi.org/10.1007/s00705-011-0987-y

Other articles of this Issue 8/2011

Archives of Virology 8/2011 Go to the issue

Original Article

DNA genome of spontaneously occurring deletion mutants of herpes simplex virus type 1 lacking one copy of the inverted repeat sequences of the L component

Original Article

A nationwide survey of hepatitis E virus (HEV) infection in wild boars in Japan: identification of boar HEV strains of genotypes 3 and 4 and unrecognized genotypes

Brief Report

Detection and molecular characterisation of rotavirus and norovirus infections in Jordanian children with acute gastroenteritis

Original Article

Uniformity of rotavirus strain nomenclature proposed by the Rotavirus Classification Working Group (RCWG)

Original Article

Antiviral activity and possible mechanisms of action of pentagalloylglucose (PGG) against influenza A virus

Original Article

Detection of hepatitis C virus by an improved loop-mediated isothermal amplification assay
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits